首页|三氟甲基喹唑啉化合物抑制耐药性胶质母细胞瘤的增殖

三氟甲基喹唑啉化合物抑制耐药性胶质母细胞瘤的增殖

扫码查看
当前胶质瘤的治疗面临耐药性问题,导致传统化疗药物效果受限。本研究旨在探究三氟甲基喹唑啉化合物(KZL204)抗胶质瘤的潜在作用机制。通过CCK-8检测,我们发现KZL204能显著抑制耐药癌细胞的生长,其48 h的半数抑制浓度(IC50)为3。63±0。38 μmol/L,显著优于阳性对照药物替莫唑胺(TMZ)(IC50值为141。72±3。65 μmol/L)。此外,流式细胞仪分析显示,KZL204处理能显著提高耐药肿瘤细胞的凋亡率,并将细胞周期阻滞在G2/M期。同时,Traswell实验证实,KZL204对耐药癌细胞迁移和侵袭的抑制作用。转录物组学分析揭示,KZL204处理后耐药癌细胞中2 435个差异表达基因,其中1 320个上调,1 115个下调。KEGG和GO富集分析表明,这些差异基因显著富集在凋亡相关信号通路。进一步的生物信息学预测和韦恩图分析确定了 35个潜在的关键节点基因,其中PI3K-AKT信号通路在差异表达基因中最为显著。实时荧光定量PCR(RT-qPCR:Quantitative Real-time PCR)验证了 KZL204 对 CREB3L1、CSF1、CXCL5、BCL3 等基因的下调作用,以及对FOS、LTA、PTGS2、MAP2K3等基因的上调作用。蛋白质水平的免疫印迹检测也证实了 KZL204对凋亡蛋白质表达的影响,包括上调Bax、切割胱天蛋白酶3(cleaved caspase-3)表达,下调AKT、Bcl-2、胱天蛋白酶3和胱天蛋白酶8的蛋白质表达。综上所述,KZL204通过调控PI3K-AKT和凋亡相关信号通路,显著抑制了耐药性胶质母细胞瘤的生长和转移,并诱导细胞凋亡及阻滞细胞周期,展现了其作为抗耐药性胶质瘤候选药物的潜力。
A Novel Trifluoromethyl Quinazoline Compound Inhibits Drug-resistant Glioblastoma Cells Proliferation
The current treatment of glioma is facing drug resistance,which limits the efficacy of traditional chemotherapy drugs.This study aims to explore the potential mechanisms of the trifluoromethylquinazoline compound(KZL204)against glioma.Through the Cell Counting Kit-8(CCK-8)assay,we found that KZL204 significantly inhibits the growth of drug-resistant cancer cells,with a 48-hour half-maximal inhibitory concentration(IC50)of 3.63±0.38 μmol/L,which is significantly better than the positive control drug temozolomide(TMZ)(IC50 value of 81.67±5.49 μmol/L).Additionally,flow cytometry analysis showed that KZL204 treatment significantly increased the apoptosis rate of drug-resistant tumor cells and arrested the cell cycle at the G2/M phase.At the same time,the Transwell assay confirmed the inhibitory effect of KZL204 on the migration and invasion of drug-resistant cancer cells.Transcriptome analysis revealed 2 435 differentially expressed genes in drug-resistant cancer cells treated with KZL204,of which 1 320 were upregulated,and 1 115 were downregulated.KEGG and GO enrichment analysis showed that these differential genes were significantly enriched in apoptosis-related signaling pathways.Further bioinformatics prediction and Venn diagram analysis identified 35 potential core targets,with the PI3K-AKT signaling pathway being the most significant among the differentially expressed genes.Quantitative real-time PCR(RT-qPCR)experiments confirmed the downregulating effects of KZL204 on genes such as CREB3L1,CSF1,CXCL5,BCL3,and the upregulating effects on genes like FOS,LT A,PTGS2,MAP2K3.Immunoblotting experiments at the protein level also confirmed the impact of KZL204 on the expression of apoptotic proteins,including the upregulation of Bax,cleaved Caspase-3 protein,and the downregulation ofAKT,Bcl-2,Caspase-3,and Caspase-8 protein expression.In summary,KZL204 significantly inhibits the growth and metastasis of drug-resistant glioblastoma and induces apoptosis and cell cycle arrest by regulating the PI3K-AKT and apoptosis-related signaling pathways,demonstrating its potential as a candidate drug against drug-resistant glioma.

quinazoline compoundsdrug resistant glioblastomacell apoptosisgrowth inhibitiontransfer

陈小忠、韦仕南、骆衡、张鹏、孙萍、孙宝飞

展开 >

遵义医科大学附属医院神经外科,贵州遵义 563003

贵阳市第二附属医院神经内科,贵阳 550023

贵州省天然产物研究中心,贵阳 550016

贵州省高等学校功能与疾病人脑组织库重点实验室,贵州医科大学,贵阳 550025

展开 >

喹唑啉类化合物 耐药胶质母细胞瘤 细胞凋亡 生长抑制 转移

贵州省科技计划项目贵州省科技计划项目贵州省教育厅科技部科技创新2030-"脑科学与类脑研究"重大项目

黔科合基础-ZK[2021]一般463黔科合基础-ZK[2023]一般316黔教技[2023]015号2021ZD0201100

2024

中国生物化学与分子生物学报
中国生物化学与分子生物学会 北京大学

中国生物化学与分子生物学报

CSTPCD北大核心
影响因子:0.617
ISSN:1007-7626
年,卷(期):2024.40(9)